Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression

Acta Oncologica

Volumn 47, Issue 8, 2008, Pages 1502-1512

  Fantozzi, Ivana ^a   Grall, Dominique ^a   Cagnol, Sébastien ^a   Stanchi, Fabio ^a   Sudaka, Anne ^b   Brunstein, Marie Christine ^b   Bozec, Alexandre ^b   Fischel, Jean Louis ^b   Milano, Gerard ^b   Van Obberghen Schilling, Ellen ^a  

^a CENTRE DE BIOCHIMIE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; CORTACTIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE AMPLIFICATION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 54349111665     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802089801     Document Type: Article

References (23)

1. Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT. Identification and characterization of a novel cytoskeletonassociated pp60src substrate. Mol Cell Biol 1991;11:5113-24.
2. Schuuring E, Verhoeven E, Litvinov S, Michalides RJ. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 1993;13:2891-8.
3. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J 2004;382(Pt 1):13-25.
4. Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997;15:1617-23.
5. Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:3177-82.
6. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-61.
7. Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: Comparison with Epidermal Growth Factor Receptor status. Br J Cancer; (in press).
8. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
9. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
10. Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 2005;65:3273-80.
11. Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006;95:722-8.
12. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-23.
13. Vouret-Craviari V, Boulter E, Grall D, Matthews C, Van Obberghen-Schilling E. ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells. J Cell Sci 2004;117(Pt 19):4559-69.
14. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD. Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996;12:31-5.
15. van Rossum AG, de Graaf JH, Schuuring-Scholtes E, Kluin PM, Fan YX, Zhan X, et al. Alternative splicing of the actin binding domain of human cortactin affects cell migration. J Biol Chem 2003;278:45672-9.
16. Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998;273:25770-6.
17. Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 2005;27:710-7.
18. Lynch DK, Winata SC, Lyons RJ, Hughes WE, Lehrbach GM, Wasinger V, et al. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 2003;278:21805-13.
19. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: An emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8:349-57.
20. Cheng Y, Leung S, Mangoura D. Transient suppression of cortactin ectopically induces large telencephalic neurons towards a GABAergic phenotype. J Cell Sci 2000;113(Pt 18):3161-72.
21. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006;66:8017-25.
22. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007;67:9304-14.
23. Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 2000;89:286-92.